Innovative Cellular Therapeutics Holdings Ltd 4

What Happened Innovative Cellular Therapeutics Holdings Ltd, reported as a 10% owner of Lyell Immunopharma (LYEL), sold 10 shares on July 17, 2026 at $13.70 per share, grossing $137. The Form 4 lists the transaction as an open market or private sale (code S). This is a small divestiture versus the holder’s existing position and typically considered routine selling rather than a major signal of sentiment.

Key Details

• Transaction date: 2026-07-17; price: $13.70; shares sold: 10; proceeds: $137.
• Shares beneficially owned immediately prior to the sale: 2,857,490; after the sale: 2,857,480. (Footnote indicates the pre-sale total and that 10 shares were sold.)
• Filing: Form 4 filed with accession 0001140361-26-028955 on 2026-07-20 (period of report 2026-07-17). No late-filing indication in the record.
• Transaction code: S (sale). No 10b5-1 plan, tax withholding, or option exercise noted in this filing.

Context As a 10% holder, Innovative Cellular is an institutional/major shareholder rather than a company executive; small sales like this (10 shares for $137) are typically administrative or routine and should not be over-interpreted as a change in outlook. Retail investors should weigh insider transactions alongside other signals (size, pattern, and timing) rather than a single, very small sale.